Background
==========

Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency affecting more than 400 million people worldwide \[[@B1]\].

The G6PD gene is located on the Xq28 region of the X chromosome and is about 20 kb in length comprising 13 exons and 12 introns \[[@B2]\]. Although G6PD is a house keeping enzyme that is expressed in all tissues, clinical manifestations of its deficiency are seen almost exclusively in red cells (RBC) including: neonatal jaundice and acute hemolytic anemia related to drugs, infection, or the ingestion of fava beans \[[@B2],[@B3]\]

G6PD enzyme (G6PD) is known to protect RBCs from the harmful effects of reactive oxygen species. Mutations in G6PD gene that reduce the amount of G6PD enzyme or alter its structure cause hemolytic anemia as a result of accumulation of reactive oxygen species \[[@B2]\]. More than 200 mutations have been reported showing different distributions in different populations, with sharing of specific mutations within each population \[[@B4]\].

G6PD deficiency has been reported in almost all racial groups with prevalence rates ranging from less than 1% in Japan and Northern European populations to a high of 58% in Kurdish Jews \[[@B5]-[@B7]\]. High rates of G6PD deficiency have been reported from the Mediterranean Littoral, Middle East, Africa and south and south East Asia \[[@B1]\].

Previous studies on G6PD deficiency in Iraq focused on the prevalence rates in various parts of the country and among its two major ethnic groups namely: the Arabs and Kurds \[[@B8]-[@B12]\]. Only one study done on the Kurds of northern Iraq tackled the molecular aspects of G6PD-deficient variants \[[@B12]\]. The aim of the current study is to determine the prevalence of G6PD deficiency and characterize the deficient variants and their enzyme levels among asymptomatic healthy blood donors in the Arab population of central Iraq and to compare the findings with those reported among the Kurds in the North as well as among neighboring countries.

Methods
=======

A total of 1810 healthy adult male blood donors were randomly recruited from the National Blood Transfusion Center in Baghdad, Iraq from 28^th^April to 26^th^August 2008. They were classified into G6PD deficient and G6PD non-deficient individuals according to the result of Methemoglobin Reduction Test (MHRT) \[[@B13]\]. Deficiency was subsequently confirmed by quantitative enzyme assays according to the manufacturer instructions (Biolabo-France). G6PD enzyme assays were also performed on an additional 49 random G6PD non-deficient individuals as controls.

DNA from deficient cases was extracted from whole blood by phenol-chloroform method. The extracted DNA was screened sequentially for four G6PD deficient mutations namely G6PD Mediterranean (563 C→T), G6PD Chatham (1003 G→A), G6PD A- (202 G→A) and G6PD Aures (143 T→C). A subset of those with the Mediterranean variant were then screened for the silent (1311 C→T) mutation using a polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) based method \[[@B12]\].

This research was approved by the ethical committee at the college of Medicine, University of Baghdad, Baghdad-Iraq, and informed consents were obtained from all participants.

Statistical analysis utilized the Mann Whitney U test, and a p \< 0.05 was considered significant.

Results
=======

Among 1810 individuals enrolled in this study, 109 (6.0%) were found to be deficient by MHRT and then confirmed by enzyme assays.

Adequately extracted DNA samples from 101 of 109 deficient cases were included in further molecular studies. The remaining 8 samples were either inadequate or had failed DNA extraction.

Among 101 G6PD deficient males, the Mediterranean variant (563 C→T) was detected in 75 (74.3%), G6PD Chatham (1003 G→A) in 5 (5.0%), and G6PD A- (202 G→A) in 2 (2.0%) individuals. None of the remaining 19 cases showed the G6PD Aures (143 T→C) when tested for this variant. Table [1](#T1){ref-type="table"} outlines G6PD enzyme levels among those with the Mediterranean, Chatham and A- variants as well as the non-deficient controls. The enzyme levels were least among the Mediterranean, and they were significantly lower than those with the Chatham variant (*p*= 0.001).

###### 

The G6PD enzyme levels (in IU/g Hb) in the three deficient variants identified in the current study and the control non-deficient group

  Variant                  Number   Range        Mean ± SD    Median
  ------------------------ -------- ------------ ------------ --------
  Mediterranean            75       0.16-0.89    0.35+0.14    0.35
                                                              
  Chatham                  5        0.44-1.17    0.73+0.28    0.71
                                                              
  A-                       2        2.10, 1.75                
                                                              
  Non-deficient controls   49       8.11-15.1    11.27+2.16   11.20

Among the 101 deficient individuals screened in this study, only one person with the Mediterranean variant gave a history suggestive of an acute hemolytic episode in his childhood, following the ingestion of fava beans (favism). Family history, however, indicated that in 15 individuals with the Mediterranean variant and 2 with the Chatham variant, there were episodes suggestive of acute hemolysis in one or more of their family members.

Among 51 cases with the Mediterranean variant, 48 (94.1%) showed the presence of the silent 1311 mutation (1311 C→T).

Discussion
==========

Baghdad lying at the center of Iraq was established as the Capital at the time of the Abbasid Empire (762-1258 AD). Current day Iraq coincides with ancient Mesopotamia that is labeled \"the Cradle of Civilization\" having witnessed some of the most ancient civilizations dating back to 7000 years. This fertile and rich land was throughout its history an attraction for invaders including Persians, Greeks, Romans, Mongols and Turks with variable impact on the mainly Arab population of Iraq \[[@B14]\].

G6PD deficiency has long been recognized as a common inherited hematological disorder among Iraqis \[[@B8],[@B9]\] with reported rates of 6.0-15.3% \[[@B8]-[@B12],[@B15]\]. This study gave a rate of 6.0% among males in Baghdad, a figure that lies closer to the lower limit of previously reported range in this city of 6.1-12.3% \[[@B8]-[@B10]\]. This might be explained by the nature of this study where the subjects were male blood donors; it is expected that blood donation is not a common practice among individuals who could have experienced the hemolytic anemia of G6PD deficiency. Studies from Arab and neighboring countries showed a remarkable variation in the frequency of G6PD deficiency, even within the same country (Figure [1](#F1){ref-type="fig"}) \[[@B6],[@B16]\]. Such variation maybe attributed to variable G6PD gene flow from Southern Europe and Africa, as well as on the presence of ethnic variations and the endemicity of malaria. G6PD deficiency is known to offer selective heterozygote advantage against certain malaria species in endemic areas \[[@B1],[@B2]\].

![**The prevalence rates of G6PD deficiency and the most common deficient variants among males in Iraq and some of the surrounding populations**\[[@B6],[@B8]-[@B12],[@B16]-[@B32],[@B38],[@B42]-[@B56]\].](1471-2326-12-4-1){#F1}

The current study revealed that the most common G6PD deficient molecular variant was G6PD Mediterranean detected in 74.3% of deficient males. The Mediterranean mutation is the most common mutation in Asian Arab countries and Egypt, with frequencies ranging from a low of 53.6% in Jordan to a high of 91.2% in Bahrain \[[@B17]-[@B22]\], while it is the second most common variant in some African Arab countries like Algeria and Tunisia with frequencies of 23% and 11.4% respectively \[[@B23],[@B24]\]. The Mediterranean mutation is also the most frequent mutation among Iraqi Kurds (87.8%), in neighboring Turkey (80%), Iran (66.2%-91.2%), Southern Europe (69-77%) and the Indian subcontinent (60.4-79.6%) \[[@B12],[@B25]-[@B32]\] (Figure [1](#F1){ref-type="fig"}). The mutation decreases in frequency as we move east, though it is still present in polymorphic frequencies in Malaysia and Indonesia \[[@B33],[@B34]\]. The association of the Mediterranean mutation with a silent 1311 mutation (1311 C→T) noted in Arab and other countries in the Middle East as well as southern Europe \[[@B21]-[@B23],[@B35],[@B36]\], is consistent with the notion of the common origin of this mutation in the Mediterranean basin within the past 1600 to 6640 years, and thereafter spreading to Middle east, and north Africa in the first millennium BC, where it was selected for by malaria already highly endemic in these fertile agricultural lands, particularly around 500 BC and thereafter \[[@B37]\]. In contrast to the latter, studies from Indian subcontinent (India and Pakistan) have documented that their Mediterranean mutation is much more likely to be associated with 1311C, suggesting a separate origin of the mutation in that part of the world \[[@B29],[@B30],[@B36]\].

The second most frequent variant detected in this study was G6PD Chatham, which was found in 5.0% of G6PD deficient individuals. Studies from other Arab countries showed variable rates of 10.1% in Kuwait, 3.6% in Jordan and 1% in Algeria \[[@B17],[@B18],[@B23]\], while it was encountered in 8.7% of Iraqi Kurds, 4% in Turkey and 2.2-27% in Iran\[[@B12],[@B25]-[@B28]\]. G6PD Chatham is now recognized as one of the common variants worldwide \[[@B17],[@B23],[@B26]\], and in addition to Mediterranean countries, it has also been reported in polymorphic frequencies in Spain, India, Malaysia and Indonesia \[[@B29],[@B33],[@B38],[@B39]\].

In this study, the African A- variant was present in only 2% of deficient males, a rate that is lower than the figures reported in some Asian Arab countries, where it is the second most common variant with rates of 5.8-16.7% \[[@B17]-[@B20]\]. The A- variant is the most frequent variant in some African Arab countries like Tunisia and Algeria with rates of 63.6% and 46% respectively \[[@B23],[@B24]\]. The latter is anticipated since the A- mutation is almost the sole mutation responsible for G6PD deficiency in tropical Africa (Figure [1](#F1){ref-type="fig"}) and it is common in areas where people of African origin are present \[[@B2]\]. Our earlier study on Iraqi Kurds failed to document any case with the A- variant, while reports from neighboring Turkey and Iran reported rates of 2% and 0-1.35% respectively \[[@B12],[@B25]-[@B28]\]. Such variability in the distribution of the African A- mutation could be explained by the different gene flow of this variant in African and Asian Arab countries. Future studies in Southern Iraq, where African gene flow is historically documented, may show results similar to those found in the Arabian Peninsula.

G6PD Aures was first described in an Algerian boy in 1993 \[[@B40]\], and later found to account for 7% of deficient variants in Algeria \[[@B23]\]. Thereafter, reports on this variant appeared from several Arab countries including Tunisia, Jordan, Kuwait, UAE and Western Saudi Arabia with frequencies of 4.5, 3.6, 3.0, 16.7 and 17% respectively \[[@B17],[@B18],[@B20],[@B24],[@B41]\]. None of the 19 uncharacterized cases in the current study showed this variant.

An intriguing observation relevant to the clinical phenotype associated with the Mediterranean variant (known to be a class II severe variant) in the current study is that only one individual (1.3%) with the latter variant had a personal history suggestive of favism. This should be viewed in the context of the design of the current study, which is based on screening apparently healthy individuals (blood donors), and maybe due to several causes including the possibility that some donors have had mild unnoticeable hemolytic episodes, or that those with documented favism may have refrained from blood donation voluntarily. Moreover, it is well known that hemolysis following bean consumption is not a rule, with a lot of individual variations even in the same individual at various times, in addition to the possibility of yet unidentified genetic factors that may play a role \[[@B1]-[@B3]\]. Our observation is shared by other studies of comparable design from other populations with predominance of the Mediterranean variant, including Saudi Arabia and Greece \[[@B32],[@B42]\]. In his study including 757 apparently healthy male volunteers from Eastern Saudi Arabia, Al-Ali did not find any history of favism in any of his G6PD deficient subjects, despite the fact that they constituted 36.5-45.9% of the screened individuals, and that the Mediterranean variant is known to be their main deficient variant \[[@B19],[@B42]\]. Another study from Greece which included screening 7,680 healthy adult males, found that 299 were G6PD deficient with the Mediterranean constituting 77.3% of the variants, yet none was symptomatic despite quite low enzyme levels \[[@B32]\]. The results of our study and those reviewed above favor the notion that many G6PD deficient individuals in these populations may remain asymptomatic throughout their lives, unaware of their status \[[@B2]\].

Conclusions
===========

Three polymorphic variants, namely the Mediterranean, Chatham and A- constituted the bulk of the G6PD deficient variants among the sample population in Baghdad, a result that is comparable to findings in neighboring Arab and non-Arab countries. The results of this study on Iraqi Arabs complement those of our earlier study on Iraqi Kurds, to give a more comprehensive idea about the distribution of G6PD variants in Iraq \[[@B12]\]. An important observation of the current study is that a significant number (\~19%) of G6PD deficient cases remained uncharacterized, compared to around \~3% in our earlier study on Kurds \[[@B12]\], which is quite interesting and may reflect the much open admixture with other civilizations throughout the centuries \[[@B14]\]. DNA sequencing is necessary to determine whether these uncharacterized mutations were carried by gene flow or they represent novel mutations.
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